# OnCo record keynote-775 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-775/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-775", "NCT03517449" ;
  schema:name "KEYNOTE-775 / Study 309"@en ;
  schema:description "A pill that blocks tumour blood vessels plus immunotherapy extended survival after chemotherapy, including in tumours that immunotherapy alone does not touch."@en ;
  schema:url <https://onco.cc/trials/keynote-775/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03517449>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2108330> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2018-06-11" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/>, <https://onco.cc/cancers/endometrial-nsmp/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/eisai/> .